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Joint Site Hypermobility Non-Hypermobility p value/p value adjusted for age
mean # OA affected joints mean # OA affected joints
DIPs 0.21±0.62 0.60±1.35 0.08/0.22
PIPs 0.13±0.47 1.10±1.98 0.007/0.02
CMCs 0.026±0.16 0.15±0.49 0.13/0.26
DIPs+PIPs+CMCs 1.10±0.38 1.45±0.74 0.007/0.003
hypermobility group (7.26±0.46) vs. the non-hypermobility group
(7.42±0.64) (p=0.04). The ages of the 120 participants in the
knee examined subgroup were similar (hypermobility 51.2±15.8
years, non-hypermobility 57.6±15.8 years, p=0.06). The hyper-
mobility group showed consistently lower odds of hand OA (Table
1). The hypermobility group also showed a lower odds of knee
OA. By logistic regression, hypermobility was associated with a
decreased likelihood ratio of knee OA (p=0.012); however, after
controlling for age, the strength of the association was borderline
signiﬁcant (p=0.05). The hypermobility group also demonstrated
signiﬁcantly fewer OA affected PIP joints by examination (Table
2).
Conclusions: This cross-sectional study agrees with our pre-
vious study in a separate cohort showing that hypermobility
protects against OA of the PIP joints. We observed a similar
trend for OA of the DIP joints. This study suggests that joint
hypermobility might serve as a quantitative trait for identifying a
protective gene for OA.
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SEARCH FOR POTENTIAL OA OUTCOME BIOMARKERS
- “MULTIMARKER APPROACH”
O. Nemirovskiy1, M-P. Hellio Le Graverand2, T. Sunyer1,
M. Abrams1, P. Aggarwal1, D. Duﬁeld1, M. Radabaugh1,
A. Berglund1, W. Mathews1
1Pﬁzer, Inc., St. Louis, MO; 2Pﬁzer, Inc., Ann Arbor, MO
Purpose: Identiﬁcation of a panel of biochemical markers to
serve as surrogate biomarkers for measuring early efﬁcacy of
DMOAD therapies in OA clinical trials.
Methods: Urine, serum, and plasma cross-sectional samples
were collected from healthy and OA human subjects with symp-
tomatic OA, n = 22, subjects with no symptoms but radiographic
signs of OA (ROA) in knee/hip joints (n = 30), or ROA in
hand/spine joints (n = 18), and in subjects with no symptoms
or radiographic signs of OA (n = 12)). The diagnosis of symp-
tomatic OA (SOA) was based on a combination of pain or
stiffness on most days of a month during the past year and
the presence of radiographic OA as deﬁned by Kellgren and
Lawrence grades (KLG) 2 and 3. Samples were analyzed for
the levels of cartilage, bone, and synovium matrix degradation
and synthesis markers as well as for markers of inﬂammation.
Collagen type I neoepitope (TINE), type II (TIINE), type III (TI-
IINE), aggrecan neoepitope (Agg), and osteopontin peptides
were measured in urine by in-house developed LC-MS/MS as-
says. In plasma, 3-nitrotyrosine (3-NT) and procollagen type II
N-terminal propeptides (NPII) were measured by in-house devel-
oped immunoafﬁnity LC-MS/MS and competitive ELISA assays,
respectively. Urinary C-terminal telopeptides of type II collagen
(CTX-II) and plasma procollagen type I (PINP) and type III N-
terminal propeptides (PIIINP) were measured by published Elisa
assays. Plasma levels of prostaglandin PGE2 and 15-HETE
were determined by LC-MS/MS methods. Individual marker data
was analysed using one-way ANOVA and Bonferroni’s multiple
comparison test. Both principal component analysis (PCA) and
partial least squares (PLS) algorithms were applied to the entire
set of data.
Results: The levels of CTX-II, TIINE, TIIINE, osteopontin, PII-
INP, PGE2, 15-HETE, and 3-NT levels were signiﬁcantly higher
in symptomatic OA patients as compared to other groups (p-
values < 0.05 - 0.001). In contrast, plasma levels of NPII and
urinary levels of Agg were signiﬁcantly lower in SOA patients
as compared other groups (p-value < 0.001 for NPII, and <
0.05 for Agg). PINP and TINE levels were similar in all groups
(p-value = 0.4). The ratio of CTX-II or TIINE to NPII enhanced
the differences between SOA patients and other groups. Levels
of Agg marker were higher in the ROA in knee/hip group as
compared to no ROA or SOA groups (p value < 0.05). Unguided
PCA analysis was able to differentiate SOA subjects from the
subjects with ROA in knee/hip, hand/spine, and no ROA. Five
markers including PIIINP, pPGE2, 15-HETE, TIINE, and NP2
contributed most to the separation. Application of PLS-DA model
allowed for the separation of ROA in knee/hip group from the
ROA in hand/spine and no ROA. The most important markers
contributing to this separation were Agg, TIINE, PIIINP, PGE2,
and 15-HETE.
Conclusions: Application of biomarkers reﬂecting joint matrix
protein degradation and synthesis as well as inﬂammation may
provide a means of distinguishing subjects with symptomatic OA
from subjects showing only radiographic OA in knee/hip.
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1Nordic Bioscience, Herlev, Denmark; 2University of
Copenhagen, Copenhagen, Denmark
Purpose: The study population selection criteria are essential
for the study outcome - without a high risk of progression in the
population if left untreated, no treatment will have any chance of
demonstrating an effect. The fundamental differences between
biochemical and MRI-based biomarkers suggest that combina-
tions may be appropriate. The purpose of this study was to
evaluate whether an aggregate prognostic biomarker targeting
cartilage longevity provided better performance than the individ-
ual markers.
Methods:A randomized population of 159 subjects was prospec-
tively selected with age 56.2±15.8, 48% female, and BMI
26.3±4.2. Radiographs were acquired in a semi-ﬂexed load-
bearing position using the SynaFlex. MRI scans were acquired
on a 0.18T Esaote scanner (Turbo 3D T1: 40° FA, TR 50 ms, TE
16 ms, 0.7 x 0.7 x 0.8mm3, time 10 min). Radiographs and MRI
were acquired at baseline (BL) and at follow-up (FU) after 21
months. Fasting morning urine samples were collected (second
void) at BL. 288 left and right knees were used in the study at BL
(after 25 knees were used for training of computer-based meth-
ods) and 245 knees at FU. The Kellgren and Lawrence (KL) score
was evaluated from the radiographs in the medial tibio-femoral
compartment and cartilage volume, mean thickness, congruity
(a measure of the surface curvature), surface smoothness, and
homogeneity (the entropy of the cartilage intensity distribution)
were quantiﬁed by a fully automatic, computer-based framework
in the medial tibial (and femoral) compartments. Urinary levels
of collagen type II C-telopeptide fragments (uCTX-II) were mea-
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sured by the CartiLaps ELISA assay and corrected for urinary
creatinine levels. We used log(uCTX-II) to have approximately
normally distributed marker values.
The BL distribution of KL scores was (145,88,30,24,1) for KL 0-4.
Among the BL healthy knees (KL 0), 101 were non-progressors
at FU (KL 0) and 25 were progressors (KL > 0).
The prognostic ability was evaluated on whether the biomarker
BL values separated progressors from non-progressors with
MANOVA statistical signiﬁcance and by sample size (n) and
odds ratio (OR) for predicting progression.
An aggregate biomarkers was made by combining all biomark-
ers and the cartilage longevity marker by combining uCTX-II
with cartilage volume and homogeneity by linear discriminant
analysis. They were evaluated by repeated random sampling
of disjoint training and evaluation subsets to avoid performance
overestimation due to overtraining.
Results: The table lists p value for separating progressors from
non-progressors with the corresponding n and OR for each
biomarker. Only the compartment with best performance is listed
for the MRI markers. Also age and BMI predicted progression
(p<0.01) but not congruity and sex.
Prediction of Progression (evaluated by MANOVA p-value, sample size n, and
odds ratio OR)
Biomarker P-value n OR
JSW 0.5 – –
uCTX-II 0.004 71 6.7
Volume (MF.VC) 0.08 218 2.8
Area (MT.AC) 0.07 216 2.8
Thickness (MT.ThCtAB) 0.2 – –
Smoothness (MT.SmoC) 0.01 118 3.8
Homogeneity (MT.HomC) 0.002 69 4.9
Aggregate: All markers 0.001 50 6.3
Aggregate: Cartilage Longevity
(uCTX-II, Homogeneity, Volume) 0.00003 29 14.6
Conclusions: The results demonstrated that both biochemical
and MRI-based biomarkers were suitable prognostic biomarkers
while JSW appeared unsuited. The best individual biomarker
was uCTX-II requiring n 71 and offering OR 6.7. However, the
cartilage longevity marker combining uCTX-II, homogeneity and
volume had n 29 and OR 14.6. This prognostic marker may there-
fore provide much stronger study population selection - allowing
clinical studies to show the true effect of potential treatments.
Furthermore, the longevity marker is intuitively appealing since it
combines aspects of cartilage quantity (volume), quality (homo-
geneity), and breakdown (uCTX-II) - the natural components in
a comprehensive prognosis on expected cartilage life-span.
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AGGRECAN CONSISTS OF TWO DISTINCT POOLS: ONE
HIGH-MOLECULAR-WEIGHT, AGGRECANASE
DEGRADABLE REVERSIBLE POOL, AS WELL AS AN
IRREVERSIBLE, MMP-SUSCEPTIBLE
LOW-MOLECULAR-WEIGHT POOL
E.U. Sumer, S.H. Madsen, B-C. Sondergaard, C. Christiansen,
P. Qvist, M.A. Karsdal
Nordic Bioscience, Herlev, Denmark
Purpose: Cartilage turnover consists of both physiological and
pathological turnover. Until now, these processes have not been
separated due to lack of molecular tools. Today, it is still debated
which family of enzymes that are the major players of aggre-
can degradation under pathological conditions. Previously, we
have shown that early stage aggrecanase-mediated aggrecan
degradation was fully reversible after catabolic stimulation with
Tumor Necrosis Factor Alpha (TNFα) and Oncostatin M (OSM) in
combination, followed by anabolic treatment with Insulin Growth
Factor-I (IGF-I), whereas late stage MMP-mediated degradation
was irreversible. In this study, we further investigated the time-
dependent degradation proﬁle of proteoglycans in cartilage with
focus on MMP and aggrecanase activity and characterized these
different molecules.
Methods: Cartilage depletion was stimulated in bovine artic-
ular cartilage explants by TNFα (20ng/ml) and Oncostatin M
(OSM) (10ng/ml) treatment. Cartilage degradation was measured
by two independent immunoassays: MMP-mediated aggrecan
degradation and aggrecanase-mediated aggrecan degradation,
342FFGVG-G2 and 374ARGSVI-G2 respectively. Glycosaminogly-
cans (GAGs) were quantiﬁed by a colorimetric assay. Cell culture
supernatants were further investigated by western blots by mon-
oclonal antibody against the MMP-generated 342FFGVG neo-
epitope, or the aggrecanase-generated 374ARGSVI sequence.
Importantly because of the location of the fragments in aggre-
can, in theory, MMP-generated fragments cannot be generated
secondary to aggrecanase cleavage, but the aggrecanase site
may be generated after MMP cleavage.
Results: Cytokine stimulation resulted in early release of
aggrecanase-mediated cartilage degradation fragments at day
7, as quantiﬁed by 374ARGSVI-G2, which was increased ap-
proximately 723% and GAGs were similarly elevated by 206%.
The increases were apparent until day 11 where aggrecanase-
mediated aggrecan depletion was exhausted. In contrast, MMP-
mediated aggrecan degradation began at day 16 until the end
of the study-period, resulting in a ﬁnal increase of 1598% of
342FFGVG-G2 fragments. Western blot analysis showed high
molecular weight GAG-entailing 374ARGSVI fragments at day 7,
in contrast to low molecular weight non-glycolysated 342FFGVG
analytes at day 21. When digesting OSM/TNFα stimulated ex-
plants from day 21 in vitro with ADAMTS-4, we observed a 225%
increase in the (374ARGSVI-G2/342FFGVG-G2) ratio (P=0.04).
Conclusions: This study demonstrates that two distinct pools of
aggrecan molecules exist in the articular cartilage. Secondary,
in contrast to previous publications that MMP-processed aggre-
can can be further degraded by aggrecanases. The pool of
high-molecular weight aggrecan, susceptible for aggrecanase-
mediated degradation, may be associated with fully reversible
cartilage degradation. In contrast, low molecular weight aggre-
can, degraded by MMPs may be associated with irreversible
cartilage destruction. These data begin to provide a molecular
understanding of reversible and non-reversible cartilage turnover.
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A NEW SERUM-BASED ASSAY FOR TYPE II COLLAGEN
HELICAL PEPTIDE (SERUM HELIX-II) IS ASSOCIATED
WITH LONG-TERM RADIOLOGICAL PROGRESSION IN
KNEE OSTEOARTHRITIS
P. Garnero1, N. Charni Ben Tabassi2, F. Juillet2, R.C. Whittles3,
M. Sharif3
1INSERM U664 and Synarc, Lyon, France; 2Synarc, Lyon,
France; 33Department of Anatomy, University of Bristol, Bristol,
United Kingdom
Purpose: Degradation of type II collagen is one of the hallmarks
of cartilage damage in osteoarthritis (OA). Urinary biochemical
markers reﬂecting the degradation of the helical (Helix-II) and
C-telopeptide (CTX-II) regions of type II collagen have been
developed and levels of both markers have been shown to
be associated with more rapid radiological progression in OA.
However, urinary markers have limitations including relatively
high imprecision due to variable urine dilution and the need for
creatinine correction. In addition a precise sampling of urine is
often difﬁcult in elderly patients. To overcome these limitations it
is useful to obtain serum-based biochemical markers. The aim
of our study was to investigate the association between serum
